RUSSIA’S PHARMACEUTICAL SECTOR: GENERATING GROWTH?
Given that Russia’s pharmaceutical market is expected to grow by 9% towards 2017, reaching an estimated RUB 823.629 billion (USD 17.6 billion at the exchange rate from Q4 2014), Russia is a promising country for investment. This will encourage both the innovative growth of the pharmaceutical industry and the qualitative improvement of medicinal provisions for Russian patients. What are the prospects for Russia’s pharmaceutical market under these current conditions? How can available reserves from the partnerships between the government and the pharmaceutical industry be used to solve problems for the provision of healthcare and medicines? How can new opportunities be grasped? What stimuli will help achieve the planned targets of government programmes in the healthcare, pharmaceutical and medical industries? What influence do the regional integration processes in the EAEU have on Russia’s pharmaceutical market?
Vladimir Shipkov , Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)
Anthony Wong , General Director, AbbVie
Pheroze Khan , General Manger, BMS Central and Eastern Europe
Valeriy Koreshkov , Member of the Collegium (Minister) for Technical Regulation Issues, Eurasian Economic Commission
Eric Cornut , Chief Ethics, Compliance and Policy Officer, Novartis AG
Dmitry Morozov , President, BIOCAD
David Panikashvili , President, CJSC «ROSTA»
Larisa Popovich , Director, Institute for Health Economics, National Research University of the Higher School of Economics
Vladimir Potemkin , Deputy Governor of Kaluga Region
Alexey Repik , President, Delovaya Rossiya (Business Russia)
Oleg Fomichev , State Secretary, Deputy Minister of Economic Development of the Russian Federation
Sergey Tsyb , Deputy Minister of Industry and Trade of the Russian Federation
Olivier Charmeil , Executive Vice President and General Manager, General Medicines and Emerging Markets, Sanofi
Dmitry Yalov , Deputy Chairman of the Government of Leningrad Region